![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase I Study of Recombinant Fowlpox-CEA-TRICOM Vaccine With or Without Sargramostim (GM-CSF) or Recombinant Fowlpox-GM-CSF in Patients With Advanced or Metastatic CEA-Expressing Adenocarcinomas
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Vaccine Therapy With or Without Sargramostim in Treating Patients With
Advanced or Metastatic Cancer
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
Phase I
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
Treatment
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
Completed
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
18 and over
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
FCCC-01016 NCI-1133, NCT00028496, 1133
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Determine the toxicity of recombinant fowlpox-CEA-TRICOM vaccine with or without sargramostim (GM-CSF) or recombinant fowlpox-GM-CSF in patients with advanced or metastatic CEA-expressing adenocarcinomas.
- Determine the CEA-specific T-cell precursor frequency in patients treated with these regimens.
- Assess the immunogenicity of GM-CSF in patients treated with these regimens.
- Determine the inflammatory response and cytokine expression at the vaccination site in these patients 48 hours after vaccination.
- Correlate telomere length of leukocytes with prior cytotoxic therapies and immunologic response in patients treated with these regimens.
Entry Criteria Disease Characteristics:
- Histologically confirmed adenocarcinoma that failed standard curative
options
and for which no standard palliative options are required within the
next 8
weeks
- Advanced or metastatic disease
- Recurrent or unresectable disease
- Microscopic metastatic disease confirmed by surgical
exploration allowed
- CEA expression by immunohistochemistry
OR
- Circulating CEA greater than 5 ng/mL
- HLA phenotyping required
- HLA phenotyping must be repeated for patients who
have undergone allogeneic
bone marrow transplantation
- No clinically symptomatic brain metastases
- Patients with brain metastases who have completed
palliative radiotherapy and
have discontinued steroids are eligible
- Hormone receptor status:
Prior/Concurrent Therapy:
Biologic therapy: - See Disease Characteristics
- No prior CEA-directed active immunotherapy
- Prior CEA-directed antibody therapy allowed
- At least 4 weeks since prior immunotherapy and recovered
- No other concurrent antineoplastic biologic therapy or
immunotherapy
Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for
nitrosoureas or mitomycin) and recovered
- No concurrent antineoplastic chemotherapy
Endocrine therapy: - See Disease Characteristics
- No concurrent antineoplastic hormonal therapy
- No concurrent systemic steroids (inhaled steroids
allowed)
- Concurrent systemic mineralocorticoids (e.g., megestrol for
appetite stimulation or fludrocortisone) allowed
- Concurrent birth control pills allowed
Radiotherapy: - See Disease Characteristics
- At least 4 weeks since prior radiotherapy and recovered
- No prior radiotherapy to more than 50% of all nodal
groups
Surgery: - See Disease Characteristics
- Recovered from prior surgery
- No prior splenectomy
Other: - Concurrent non-steroidal anti-inflammatory drugs
allowed
- No other concurrent anti-cancer therapy
Patient Characteristics:
Age: Sex: Menopausal status: Performance status: Life expectancy: Hematopoietic: - WBC at least 3,000/mm3
- Platelet count at least 100,000/mm3
Hepatic: - Bilirubin less than 1.5 times upper limit of normal
(ULN)
- AST and ALT less than 3 times ULN
- PT and PTT less than 1.5 times ULN (unless therapeutically
anticoagulated)
Renal: - Creatinine less than 1.5 mg/dL
OR - Creatinine clearance greater than 60 mL/min
- Proteinuria or hematuria less than +2 on urinalysis*
OR - Urine protein less than 1,000 mg/24-hour collection, if proteinuria greater than +1
[Note: Proteinuria of +2 allowed provided etiology is non-renal] Gastrointestinal: - No frequent vomiting or severe anorexia
- No more than 10% weight loss within the past 3
months
- No inflammatory bowel disease, Crohn's disease, ulcerative
colitis, or active diverticulitis
Neurologic: - No uncontrolled seizure disorders
- No encephalitis
- No multiple sclerosis
Immunologic: - No allergy to eggs
- No HIV-associated opportunistic infection
- No autoimmune diseases, including the following:
- Systemic lupus erythematosus
- Sjögren's syndrome
- Scleroderma
- Myasthenia gravis
- Goodpasture syndrome
- Addison's disease
- Hashimoto's thyroiditis
- Graves' disease
- Antinuclear antibody positive status allowed if no evidence of
an autoimmune disease
Other: - No direct contact of vaccination site with the following
persons for at least 72 hours after each vaccination:
- Children under 1 year of age
- Pregnant women
- Individuals with eczema or other open skin
condition
- Immunocompromised individuals
- No other concurrent serious medical illness that would
preclude study entry
- No other malignancy within the past 2 years except excised
basal cell or squamous cell skin cancer or carcinoma in situ of the
cervix
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception for at least
1 month before (female patients only), during, and for at least 3
months after study participation
Expected Enrollment A total of 48 patients will be accrued for this study within 1.2 years. Outline This is a dose-escalation study. The first three cohorts of 3-12 patients receive escalating doses of
recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at
which 2 of 6 patients or 3 of 12 patients experience dose-limiting toxicity.
fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then
every 2 months thereafter (beginning on day 56) in the absence of disease
progression or unacceptable toxicity. The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD
in the same manner as the first three cohorts combined with escalating doses
of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily
beginning on the day of each vaccination and continuing for a total of 4
days. The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the
MTD in the same manner as the first three cohorts combined with escalating
doses of recombinant fowlpox-GM-CSF (rF-GM-CSF). rF-GM-CSF is administered in
the same manner as GM-CSF. Patients are followed every month for 4 months.
Trial Contact Information
Trial Lead Organizations Fox Chase Cancer Center - Philadelphia ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Margaret von Mehren, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Ph: 215-728-3545; 888-369-2427 |
| ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients with Advanced CEA Expressing Adenocarinomas | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 2002-01-28 | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00028496 | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 2001-10-24 | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2003-08-29 | ![](https://webarchive.library.unt.edu/eot2008/20081015131809im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | CA06927 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |